Ilana Hellmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ilana Hellmann has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Maya Koren-Michowitz
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2 shared publications - Ofir Wolach
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
2 shared publications - Amir Aviram
Sunnybrook Health Sciences Centre, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and the University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada
1 shared publication - Anatoly Nemets
Barzilai Medical Center, Ashkelon 78306, Israel
1 shared publication - Arie Apel
Department of Hematology, Shamir Medical Center (formerly Assaf Harofe Medical Center), Zerifin, Israel, Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
1 shared publication - Baher Krayem
Rambam Health Care Campus, Haifa 3109601, Israel
1 shared publication
Latest Publications
- 20 December 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (36) , 5592-5593
Gift of Truth
- 20 December 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (36) , 5592-5593
Gift of Truth
- Open Access
- 9 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5865
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.
- 9 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5865
Open AccessMDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.
- 20 February 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (6) , 1321-1322
Guilt and Gratitude
Guilt and Gratitude: Guilt surrounding toxic consequences of chemotherapy and gratitude to patients for acknowledging the need of the physician to know they are ok and moving on with their lives.
- 20 February 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (6) , 1321-1322
Guilt and Gratitude
Guilt and Gratitude: Guilt surrounding toxic consequences of chemotherapy and gratitude to patients for acknowledging the need of the physician to know they are ok and moving on with their lives.
- Open Access
- 30 June 2019
- Published by Wiley in HemaSphere
- Vol. 3 (S1) , 95
PF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION ‐ A MULTI‐CENTER HISTORICAL CONTROL STUDY
Background: The phase 3 RATIFY trial demonstrated that adding the FLT3 inhibitor midostaurin to intensive chemotherapy improves outcome in younger patients with de‐novo FLT3‐mutated (FLT3+) AML. The toxicity and efficacy profile of adding midostaurin to chemotherapy in patients not originally included in the RATIFY study is unknown.Aims: To characterize midostaurin safety and efficacy in a ’real‐world’ setting.Methods: FLT3+ (ITD/TKD) Patients with AML (>18 years) were eligible to receive midostaurin in Israel since April 2016. To control for toxicity and efficacy outcomes the results of midostaurin‐treated patients were compared to historical controls (FLT3+ AML diagnosed after January 2015). Data were extracted from patients’ records and collected from 5 centers in Israel. Patient and disease characteristics, event free (EFS) and overall survival (OS) were analyzed and compared between the groups.Results: Forty‐eight patients were included in the analysis with a mean follow up of 10.9 ( ± 9.3) months; 33 patients were treated with midostaurin and 15 patients were included in the historical control group. The median age of patients was 61 (range 27–78) years; 33% and 23% of the patients were older than 65 and 70 years, respectively. No differences were noted between the 2 group in terms of age, gender, performance status and comorbidity scales, presenting blood counts, extramedullary involvement, leukemia ontogeny and cytogenetics apart from NPM1‐mutation which was more prevalent in the midostaurin group (69.6% vs. 40%, p = 0.051). No differences were noted between the groups in terms of induction regimen or in cytarabine dosing for consolidation.Midostaurin was administered with 90 mg/m2 daunorubicin in 11 patients (33%, comparable to control group). More patients in the midostaurin group received consolidation treatment (73% vs. 27%, p = 0.003). A full 14‐day midostaurin course was given to most patients during induction (72%). Ten patients (30%) experienced dose reductions or interruptions at different phases of therapy.Overall toxicity was comparable between the groups including febrile neutropenia rates (91% vs 93% of patients, respectively) and time to neutrophil and platelets recovery. Frequent (>10%) non‐hematologic toxicities recorded were skin rash, gastrointestinal and hepatic toxicity, thrombotic events and HSV infections (comparable between groups). QTc prolongation led to discontinuation of midostaurin treatment in one patient. Adding midostaurin to 90 mg/m2 daunorubicin for induction was not associated with excess toxicity.CR/CRi rates were 81% and 58% in the midostaurin and control groups, respectively (p = 0.13).Significantly more patients in the midostaurin group were transplanted in first remission (80% vs. 20%, p = 0.052). OS and EFS were higher, though not statistically significant, in the midostaurin vs. control group [not reached vs. 9 months (p = 0.09) and 13 vs. 5 months (p = 0.155), respectively; median follow‐up 8 months]. FLT3 allelic burden and NPM1 status did not affect survival.Summary/Conclusion: In this ‘real‐life’ setting, midostaurin was administered across all age groups, was well tolerated and did not add to toxicity, even when administered with higher doses of daunorubicin for induction. Significantly more patients in the midostaurin group were transplanted in first remission compared to historical controls and a trend toward higher overall survival was observed. Longer follow‐up and more patients are needed to assess the efficacy of adding midostaurin to chemotherapy in the off‐trial setting.
- 30 June 2019
- Published by Wiley in HemaSphere
- Vol. 3 (S1) , 95
Open AccessPF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION ‐ A MULTI‐CENTER HISTORICAL CONTROL STUDY
Background: The phase 3 RATIFY trial demonstrated that adding the FLT3 inhibitor midostaurin to intensive chemotherapy improves outcome in younger patients with de‐novo FLT3‐mutated (FLT3+) AML. The toxicity and efficacy profile of adding midostaurin to chemotherapy in patients not originally included in the RATIFY study is unknown.Aims: To characterize midostaurin safety and efficacy in a ’real‐world’ setting.Methods: FLT3+ (ITD/TKD) Patients with AML (>18 years) were eligible to receive midostaurin in Israel since April 2016. To control for toxicity and efficacy outcomes the results of midostaurin‐treated patients were compared to historical controls (FLT3+ AML diagnosed after January 2015). Data were extracted from patients’ records and collected from 5 centers in Israel. Patient and disease characteristics, event free (EFS) and overall survival (OS) were analyzed and compared between the groups.Results: Forty‐eight patients were included in the analysis with a mean follow up of 10.9 ( ± 9.3) months; 33 patients were treated with midostaurin and 15 patients were included in the historical control group. The median age of patients was 61 (range 27–78) years; 33% and 23% of the patients were older than 65 and 70 years, respectively. No differences were noted between the 2 group in terms of age, gender, performance status and comorbidity scales, presenting blood counts, extramedullary involvement, leukemia ontogeny and cytogenetics apart from NPM1‐mutation which was more prevalent in the midostaurin group (69.6% vs. 40%, p = 0.051). No differences were noted between the groups in terms of induction regimen or in cytarabine dosing for consolidation.Midostaurin was administered with 90 mg/m2 daunorubicin in 11 patients (33%, comparable to control group). More patients in the midostaurin group received consolidation treatment (73% vs. 27%, p = 0.003). A full 14‐day midostaurin course was given to most patients during induction (72%). Ten patients (30%) experienced dose reductions or interruptions at different phases of therapy.Overall toxicity was comparable between the groups including febrile neutropenia rates (91% vs 93% of patients, respectively) and time to neutrophil and platelets recovery. Frequent (>10%) non‐hematologic toxicities recorded were skin rash, gastrointestinal and hepatic toxicity, thrombotic events and HSV infections (comparable between groups). QTc prolongation led to discontinuation of midostaurin treatment in one patient. Adding midostaurin to 90 mg/m2 daunorubicin for induction was not associated with excess toxicity.CR/CRi rates were 81% and 58% in the midostaurin and control groups, respectively (p = 0.13).Significantly more patients in the midostaurin group were transplanted in first remission (80% vs. 20%, p = 0.052). OS and EFS were higher, though not statistically significant, in the midostaurin vs. control group [not reached vs. 9 months (p = 0.09) and 13 vs. 5 months (p = 0.155), respectively; median follow‐up 8 months]. FLT3 allelic burden and NPM1 status did not affect survival.Summary/Conclusion: In this ‘real‐life’ setting, midostaurin was administered across all age groups, was well tolerated and did not add to toxicity, even when administered with higher doses of daunorubicin for induction. Significantly more patients in the midostaurin group were transplanted in first remission compared to historical controls and a trend toward higher overall survival was observed. Longer follow‐up and more patients are needed to assess the efficacy of adding midostaurin to chemotherapy in the off‐trial setting.